Mergers and acquisitions (M&A) serve as an integral tool for BD in advancing its strategy of improving patient outcomes, reducing the cost of care, expanding access and enhancing the operations of our customers around the world. In recent years BD has completed dozens of tuck-in acquisitions including TVA Medical, Medafor, and Kiestra Lab Automation, and we continue to seek out attractive opportunities which align with the strategies of BD’s businesses and regions.
BD has developed leading capabilities in transactional structuring, execution, due diligence and integration. BD's Corporate Development team partners with our businesses, functions and regions to evaluate potential opportunities. All M&A opportunities should be directed to our Corporate Development team based out of our global headquarters in Franklin Lakes, New Jersey, USA through the website submission form.
BD examines and executes on M&A opportunities that are financially attractive and aligned with our strategy. This has proven to be, and remains, an important lever as we pursue our purpose of Advancing the World of Health— Vince Forlenza, Chairman & CEO
BD seeks inorganic opportunities that advance our long-term strategy through increasing patient access, driving better outcomes, managing system cost pressures, and improving health care safety. Directional criteria is provided below:
- Differentiated technologies
- Attractive underlying market growth
- Global reach and application
- Digital and connected devices / solutions
- Vascular access management
- Medication management
- Immunology research and testing
- Infectious disease diagnostics and management
- Chronic disease management (diabetes, PAD, ESRD)
- Surgical procedures and urological disorders
Submit an opportunity